Veerhealth Care wins repeat order worth ₹1.11 crore

1 min read     Updated on 13 Jul 2026, 03:07 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Veerhealth Care has received a repeat order worth ₹1.11 crore from a domestic pharmacy network for haircare and oral care products, to be executed within 45 days. The company projects a total income of ₹105 crores and a PAT of ₹5-6 crores for FY26-27, rising to ₹156 crores and ₹9-10 crores respectively in FY27-28. Additionally, the board approved the allotment of 1 crore fully convertible warrants at ₹20.25 per share to fund expansion.

powered bylight_fuzz_icon
45314160

*this image is generated using AI for illustrative purposes only.

Veerhealth Care has secured a repeat order worth ₹1.11 crore from a leading domestic network of pharmacies and healthcare companies for the supply of haircare and oral care products. The order is valued at ₹1,11,39,950 and must be executed within 45 days. This transaction is classified as a domestic order and does not involve any interest from the promoter, promoter group, or group companies of Veerhealth Care Limited.

Order Details

The buyer operates an extensive chain of hospitals across the country and maintains a nationwide presence. This repeat order underscores the trust placed in the company's capabilities to deliver quality healthcare products. The disclosure was made in compliance with Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Outlook

The company has provided financial guidance for the upcoming fiscal years. For F.Y. 2026-27, Veerhealth Care expects a Total Income of ₹105 crores with a Profit After Tax (PAT) of minimum ₹5-6 crores. For F.Y. 2027-28, the company anticipates a Total Income of ₹156 crores with a PAT of minimum ₹9-10 crores.

Corporate Actions

The Preferential Issue Committee has approved the allotment of 1,00,00,000 fully convertible warrants. Each warrant carries a right to subscribe to one equity share at an issue price of ₹20.25. Of these, 45,37,000 warrants are contributed by Promoters. The Book Value per share for FY26 is ₹11.46, which is expected to increase substantially with the infusion of funds from these warrants.

Key Order Information

Parameter Details
Value ₹1.11 Crores
Nature Supply of haircare and oral care products
Origin Domestic Entity
Execution Period 45 Days
Promoter Interest No

Historical Stock Returns for Veerhealth Care

1 Day5 Days1 Month6 Months1 Year5 Years
+2.24%+19.28%+56.40%+110.00%+92.14%+281.26%

How will Veerhealth Care manage the operational scaling required to meet the aggressive revenue guidance of ₹156 crores by FY 2027-28?

Does this repeat order signal a potential shift in the company's product mix towards higher-margin haircare and oral care segments?

What strategic initiatives are being undertaken to expand the client base beyond the current leading domestic network to sustain growth?

Veerhealth Care secures USFDA approval for OTC exports

2 min read     Updated on 27 Jun 2026, 02:54 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Veerhealth Care Ltd secured USFDA approval for OTC products in June 2025, opening the U.S. export market. Revenue for Q4FY26 rose to ₹16.76 crore from ₹5.62 crore in the prior year, with a net profit of ₹0.40 crore. The company projects future sales growth to ₹152.47 crore, supported by facility upgrades and a new FMCG partnership.

powered bylight_fuzz_icon
44097870

*this image is generated using AI for illustrative purposes only.

Veerhealth Care Ltd has received approval from the United States Food and Drug Administration (USFDA) for its Drug (OTC) products, enabling the company to export to the U.S. market. The approval, granted in June 2025, follows the successful completion of a USFDA audit in April 2025. This development positions the small-cap entity to compete with larger players and attract high-volume export orders, aligning with its "LOCAL to GLOBAL" vision.

The company reported revenue of ₹16.76 crore for the fourth quarter of the fiscal year 2026 (Q4FY26), compared to ₹5.62 crore in the corresponding period of the previous year. For the full fiscal year 2025-26, revenue stood at ₹32.48 crore, up from ₹16.87 crore in FY24-25. The financial results reflect the impact of the company's expanded operations and strategic focus on the pharmaceutical and cosmetic manufacturing sectors.

Operational Expansion and Strategic Partnerships

To support its export ambitions, Veerhealth Care has expanded and upgraded its manufacturing facilities to meet USFDA standards. The company recently onboarded a leading FMCG company operating in the domestic and international markets within the 'personal and household care' segment. This partner is part of a 125-year-old prominent business group, which is expected to contribute to future revenue growth.

The company operates a manufacturing facility with a built-up area of 90,000 sq. ft. and specializes in producing Pure Vegetarian toothpaste and cosmetic products. Its manufacturing capacity includes equipment such as ContraMixers and Oral Liquid Tanks, while its filling and packaging capabilities can handle up to 0.75 million tubes per month.

Financial Performance and Projections

Veerhealth Care's net profit for Q4FY26 was ₹0.40 crore, a turnaround from a loss of ₹-0.10 crore in the same quarter of the previous year. For the full year FY25-26, the company reported a total comprehensive income of ₹0.39 crore. Management has provided projections for the upcoming fiscal years, estimating net sales of ₹102.98 crore and ₹152.47 crore for the next two periods respectively.

Financial Highlights (Amount in ₹ Crore)

Particulars Q4FY26 Q4FY25 FY25-26 FY24-25
Revenue from Operations 16.76 5.62 32.48 16.87
Total Comprehensive Income 0.40 -0.10 0.39 0.23
Raw Material Costs 14.12 4.50 30.02 11.40

The company's product portfolio includes the Ayuveer brand, covering hair care, skin care, and oral care segments. Ayuveer products are available on e-commerce platforms such as Myntra, Amazon, Nykaa, and Flipkart. Additionally, Veerhealth Care offers contract manufacturing, private label services, and custom formulation to various clients.

Historical Stock Returns for Veerhealth Care

1 Day5 Days1 Month6 Months1 Year5 Years
+2.24%+19.28%+56.40%+110.00%+92.14%+281.26%

What specific timelines and volume targets has Veerhealth Care set for its initial entry into the U.S. OTC market?

How will the partnership with the 125-year-old FMCG group be structured, and what is the expected revenue contribution from this collaboration in FY27?

What capital expenditure or operational adjustments are required to scale production capacity to meet the projected sales growth of over ₹150 crore?

More News on Veerhealth Care

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:+92.14%